Our look is new. Our purpose is the same. Learn more about our brand evolution.
What does this mean for patients? An FDA Fast Track designation DOES NOT mean that the drug has been approved for use by patients. AOC 1020 is still a long […]
Patients are critical in helping to transform optimism into reality by Ken Kahtava, Chief Business Officer, FSHD Society Breakthroughs in FSHD research have identified the primary mechanism that causes FSHD. […]
If we want to control the narrative, we need to tell our stories by Brian Jude Loiacono I was formally diagnosed with FSHD in January 2019.  At that time I […]
A major breakthrough for the field of RNA therapeutics Avidity Biosciences announced today that its investigational treatment for myotonic dystrophy type 1 (DM1), called AOC 1001, can be delivered into […]
